The CONFIDENCE trial, a phase 2 study involving 807 adults with stage 2–3 CKD and T2D, aims to evaluate the effectiveness of finerenone combined with an SGLT2 inhibitor over six months. Here, SLC5A2 is linked to chronic kidney disease.